Best Investments for 2014
Catch up on Jim Cramer's thinking over the last week about PPG's Mexico deal and the market's amazing run.
Cramer will be listening to conference calls next week but says a lot of the companies are better than their stocks.
The performance of the Nikkei 225 over the last 25 years suggests money printing creates bubbles that eventually break.
The company aims to grow its production by 50% this year, but things could change next year if the price of a barrel of crude averages less than $80.
Biotech columnist Adam Feuerstein answers readers' questions about health care.
The latest example: Reams of wrongheaded hedge-fund short plays off the Ebola crisis.
It's worth paying attention to these potential portfolio killers.
Beijing-based IT superstar Lenovo, despite a record of smooth expansion, stands to lose the most from China's slowdown in smartphone shipments. Here's why.
The $3.3 billion paid by Royalty Pharma to the Cystic Fibrosis Foundation to acquire royalty rights to Vertex Pharmaceuticals' cystic fibrosis drugs suggests investors are under-estimating peak sales.
TheStreet highlights 3 stocks pushing the drugs industry lower today.
TheStreet highlights 3 stocks pushing the drugs industry higher today.
TheStreet's Jim Cramer says Agios Pharmaceuticals' positive Phase 1 data for its leukemia treatment is impressive. As a result, shares are going higher despite doubling since July.
Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.
Housing construction is finally showing signs of recovery, but not because more Americans are buying homes.
Healthcare investors are watching closely the race between Clovis and AstraZeneca to develop competing, targeted lung cancer drugs.
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics
while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a
reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a
comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and
strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV